Clinical Trials Browser

Phase 1/2 × Unknown × Pathologic Complete Response × Clear all

NCT01520558 2017-06-29

CNDO-109-AANK for AML in First Complete Remission (CR1)

Phase 1/2 Unknown

12 enrolled 11 charts

Other hematologic neoplasm

Pathologic Complete Response, Leukemia, Myeloid, Acute